REPLICor's Drug Activity in the Metabolic Syndrome
Laval, Quebec – September 19th, 2006 -- REPLICor announced today that Dr. Andrew Vaillant, REPLICor's Chief Scientific Officer, will present at the Metabolic Syndrome Conference 2006 at the Radisson Hotel in Boston, Mass., on September 26-27th, 2006,. Dr. Vaillant will present the latest company’s preclinical developments in hypercholesterolemia, obesity and other metabolic disorders.
About REPLICor:
REPLICor is a biopharmaceutical company developing applications for its novel DNA-based technology platform. REPLICor’s technology is based on the discovery that oligonucleotides have sequence independent and size dependent activities as amphipathic polymers with multiple potential clinical applications.
REPLICor has demonstrated that its two lead compounds, REP 9 and REP 9C, have the ability to interact with a wide variety of targets that are present in a variety of disease states including viral infections, metabolic disorders, amyloid related diseases and inflammatory diseases. They have also been shown to be well tolerated in multiples animal studies. REP 9 and REP 9C can readily be synthesized in large quantities in cGMP facilities. The company business strategy is to enter into alliances with major biopharmaceutical companies in order to further develop and market its products.
For more information:
Andrew Vaillant PhD, CSO
REPLICor Inc.
450-688-6068